Bal Pharma Share News - Latest Updates, Live News & More

Latest news about Bal Pharma

Bal Pharma opens 48-hour window for shareholder feedback on warrant pricing 1 day ago

Bal Pharma Limited issued an intimation on July 30, 2026, providing shareholders a 48-hour period to submit comments on a corrigendum to its postal ballot notice. The corrigendum, dated July 23, 2026, revised the issue price of convertible warrants to ₹84 from ₹81, increasing the potential capital raise to ₹8.4 crore for an API plant in Karnataka. Shareholders can modify their votes via remote e-voting, which remains open until August 8, 2026.

Bal Pharma Q4 Results: Net profit falls 34% YoY to ₹370 lakh 4 days ago

Bal Pharma seeks approval to issue warrants to promoter Jul 09, 2026

Bal Pharma appoints Shreepada ML as Company Secretary Jun 25, 2026

Bal Pharma FY26 net profit falls 13.4%, announces dividend May 30, 2026

More news about Bal Pharma

12May 26

Bal Pharma's Company Secretary & Compliance Officer Abdul Basith Resigns Effective May 11, 2026

Bal Pharma Limited has disclosed the resignation of Mr. Abdul Basith (Membership No. A70640), Company Secretary & Compliance Officer, effective close of business hours on May 11, 2026. Mr. Basith submitted his resignation on March 2, 2026, citing a decision to pursue external career opportunities, and the resignation was accepted on May 11, 2026. The company has directed all secretarial communications to secretarial@balpharma.com until a new Company Secretary & Compliance Officer is appointed. The intimation was filed pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

06Apr 26

Bal Pharma Limited Confirms Compliance with SEBI Dematerialization Regulations for Q4 FY26

Bal Pharma Limited has confirmed compliance with SEBI (DP) Regulations 74(5) for the quarter ended March 31, 2026. The company submitted details of securities dematerialized/rematerialized during the quarter to stock exchanges within prescribed time limits. The confirmation, signed by authorized signatory Shailesh Siroya, was communicated to NSE, BSE, and both depositories NSDL and CDSL.

11Feb 26

Bal Pharma Q3FY26 Results: Net Profit Surges 181.84% YoY to ₹194.62 Lakhs

Bal Pharma Limited delivered outstanding Q3FY26 results with net profit jumping 181.84% year-on-year to ₹194.62 lakhs, while revenue from operations grew 20.03% to ₹8,749.48 lakhs. The company's Board of Directors approved the unaudited financial results during their meeting on February 11, 2026, with statutory auditors SSJNB & Co providing an unmodified opinion, demonstrating strong operational efficiency and regulatory compliance.

08Jan 26

Bal Pharma Issues Postal Ballot Notice for Independent Director Appointment

Bal Pharma Limited has initiated a postal ballot process for shareholder approval of Dr. Mukesh Beekamchand's appointment as Independent Director for a five-year term. The e-voting period runs from January 9-February 7, 2026, with results expected by February 10. This follows the company's Q2 financial results showing revenue of ₹7,374.95 lakhs and net profit of ₹78.17 lakhs.

07Nov 25

Bal Pharma Defers Subsidiary Merger Decision, Citing Need for More Data

Bal Pharma Limited has postponed its decision on the proposed merger of its subsidiary, Lifezen Healthcare Pvt Ltd, with the parent company. The Board of Directors found the available data inadequate for making an informed decision during their recent meeting. The management has been instructed to re-present the proposal with all necessary details. The board meeting was held on 11.08.2025, and the company provided clarification to the stock exchange on 06.11.2025 regarding the deferred decision.

11Aug 25

Bal Pharma Reports Q1 FY2026 Results, Approves Employee Stock Option Plan

Bal Pharma Limited released its Q1 FY2026 financial results. Standalone revenue from operations was ₹6563.51 lakhs with a net profit of ₹32.31 lakhs. Consolidated revenue stood at ₹6587.09 lakhs with a net profit of ₹20.85 lakhs. The company announced its 38th AGM for September 25, 2025, to be held virtually. Book closure dates are set from September 19 to 25, 2025. The Board approved an Employee Stock Option Plan-2025, subject to shareholder approval. Auditors provided an unmodified opinion on the financial results. The company continues to operate in the 'Pharmaceuticals' segment.

29Jul 25

Bal Pharma Schedules Board Meeting to Discuss Q1 Results, ESOP, and Subsidiary Merger

Bal Pharma has scheduled a Board of Directors meeting for August 11, 2025, with a comprehensive agenda. Key items include reviewing Q1 financial results, planning the 38th AGM, considering an Employee Stock Option Plan-2025, and potentially merging subsidiary Lifezen Healthcare Pvt Ltd. A trading window closure is in effect from June 1 to August 14, 2025, for designated persons and employees.

Bal Pharma

88.09

+0.19

(+0.22%)

1 Year Returns:-9.29%

Industry Peers

Sun Pharmaceutical

1,990.50

(-0.53%)

Divis Laboratories

8,056.00

(+2.82%)

Torrent Pharmaceuticals

5,122.80

(+5.15%)

Cipla

1,473.20

(+0.46%)

Zydus Life Science

1,126.80

(+1.05%)

Lupin

2,415.00

(-0.26%)

Mankind Pharma

2,469.60

(-4.13%)

Laurus Labs

1,816.20

(+1.96%)

Dr Reddys Laboratories

1,148.10

(+0.29%)

Aurobindo Pharma

1,580.20

(+0.25%)

Get More Market Insights with

Stock Rental via SLBM

About Scanx

We’re building Scanx - to help you express your trading & investing idea, to help you analyse the markets better.

Stock Markets are the true indicator of the growth of any country's economy. We are bullish on India, we are bullish on India's prospects to be one of largest economies of the world. We believe that Stock Markets provide an unique opportunity for all Indians to participate in the growth story of India. We are enabling the same for Indians.
As financial services are becoming more accessible, there is now a large set of Indians today who are financially aware and literate. They value time and seek high quality products & services. Most screening, trading, investing platforms available today are more or less similar to each other, and they have not evolved with time. While both traders & investors have gotten smart about how they make money and build wealth, as users they have continued to use the same products, features, and platforms that were available for years with little or no innovation.
We plan to change that - a technology-led and artificial intelligence enabled platform built for super traders and long term investors.

Disclaimer:

The data and information provided on this website is for general informational and research purposes only. While we strive to ensure that the content is accurate, up-to-date, and reliable, this platform utilizes artificial intelligence (AI) tools to generate, curate, and summarize information. As such, the content may occasionally contain errors, omissions, or outdated information. All users are therefore advised to cross verify the source of the data and information.
This website does not constitute professional, legal, financial, medical, or any other form of licensed advice. Users are encouraged to independently verify any information before relying on it, especially for decisions that may have legal, financial, or personal consequences.
The views, analyses, and summaries presented on this platform may be generated or assisted by AI and do not necessarily reflect the opinions of the website owners, operators, editors, or affiliates.
We make no warranties or representations, express or implied, regarding the completeness, accuracy, reliability, suitability, or availability of the information contained on this website. Any reliance you place on such information is strictly at your own risk.
This website may include links to third-party sources or content. We do not control or endorse the nature, accuracy, or availability of those external sites and are not responsible for any content or damages arising from their use.
By using this website, you acknowledge and agree that the use of AI-generated content involves inherent limitations, uncertainties and inaccuracies, and you accept full responsibility for how you interpret and use the information provided.
We reserve the right to modify, update, or remove content and this disclaimer at any time without prior notice.

Part of Raise Financial Services

SEBI Stock Broker Registration No: INZ000006031 | Depository Participant (CDSL) ID: IN-DP-289-2016 | SEBI Research Analyst Registration No: INH000023357 Exchange Membership No. : NSE: 90133 | BSE: 6593 | MCX: 56320

Registered Office: Unit No. 2201, 22nd Floor, Gold Medal Avenue, S.V. Road, Beside Patel Petrol Pump, Piramal Nagar, Goregaon West, Mumbai - 400104